Purpose Our meta-analysis was undertaken to evaluate the efficacy and safety of nebivolol
compared with other second-generation β blockers for hypertensive patients. Methods We …

Background and objective Lowering BP to normal levels without quality of life deterioration
is the most important means of reducing cardiovascular risk. Recent studies have …

This double‐blind, multicenter, randomized placebo‐controlled study evaluated the
antihypertensive efficacy and safety of nebivolol, a selective β1‐adrenoreceptor blocker with …

Nebivolol is a novel, β1-adrenergic receptor blocker with vasodilatory properties mediated
through the activation of the l-arginine/nitric oxide pathway. Short-term randomized clinical …

Hypertension is a major cardiovascular risk factor but most patients remain asymptomatic for
many years. Successful therapy not only needs to be effective, it also needs to be well …

Background: Nebivolol is a third-generation β1-selective β-blocker that is approved for the
treatment of hypertension. Objective: This article reviews the clinical pharmacology of …

Objective: The efficacy and safety of nebivolol in patients with hypertension is well
established, but its effect in Asian patients with essential hypertension in the real world has …

Background: The antihypertensive activity of beta-blockers generally increases during the
first 6 to 8 weeks of treatment; however, no study has systematically assessed whether blood …

Objective: The aim of the present study was to evaluate the antihypertensive efficacy of the
highly beta 1-selective adrenergic antagonist nebivolol in comparison with bisoprolol in the …

Abstract β-Adrenergic receptor blockers (β-blockers) are well-known useful and cost-
effective drugs for managing hypertensive patients with coronary heart disease, stroke, and …